Hemophilic patient for emergency spinal decompression by Rajesh, M C et al.
Vol 4 | Issue 2 | Mar - Apr 2018 Indian J Case Reports 115
Case Report
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Hemophilia is an X-linked recessive disorder with a worldwide 
incidence of around 1 in 5000 male births [1]. Basic defect is the 
absence or deficiency of clotting Factor VIII (Hemophilia A) or 
clotting Factor IX (Hemophilia B). Although available data are 
limited in India; published census show an incidence of nearly 
1 in 10,000 live male births [2]. Occasionally they can present 
as an acquired form of the disease by the development of auto-
antibodies against their own Factor VIII or in hematological 
malignancies [3]. Bleeding manifestations in hemophilia - A 
patients parallel with the decrease in Factor-VIII levels [4]. Easy 
bruising in the childhood, spontaneous bleeding especially in the 
joints and excessive bleeding following minor traumas or surgery 
are typical histories they narrate. Laboratory investigations 
usually show a prolonged activated partial thromboplastin time 
(aPTT), but a definitive diagnosis depends on Factor VIII assay 
levels.
The main challenges in handling hemophilic patients in the 
perioperative period are to monitor and maintain optimal Factor 
VIII level and detecting and dealing with cases of Factor VIII 
antibodies. Conventional replacement therapy will be ineffective 
in a case of hemophilic - A patient with high antibody titer. 
Alternative therapy with bypassing agentsis required in such 
scenarios. Routine history taking will reveal patients coagulation 
status and hereditary nature of the disease. Essentially managing 
hemophilic patients in the perioperative period involves close 
interaction between anesthesiologist, surgeon, hematologist, 
and blood bank personnel. As soon as surgery plan is fixed, the 
pharmacy should be notified about the expected requirement of 
Factor VIII.
CASE REPORT
A 60-year-old male patient of known hemophilic (Hemophilia 
A) presented with sudden onset of weakness of both lower limbs 
of 5 days duration. Started as heaviness of both lower limbs 
followed by difficulty in walking and retention of urine. He is 
hypertensive on Amlodipine Besylate 5 mg once daily. Two of his 
uncles had a history of hemophilia. 10 years back he underwent 
piles surgery, following which he had continuous bleeding. 
He had to be transfused with 25 units of blood, two ampoules 
of Factor VIII and cryoprecipitate to stop bleeding at that time. 
There is also the history of excessive bleeding episodes following 
dental extractions in childhood, which required transfusions. 
There was also the history of joint pains and swellings, which 
used to subside with bed rest and ice packs.
Clinical examination revealed Grade V power of both upper 
limbs and Grade 0 in both lower limbs. There was sensory deficient 
below 10th dermatomal level bilaterally. Magnetic resonance 
imaging spine showed destructive marrow lesion in 9th vertebral 
body with the possibility of neoplastic lesions such as solitary 
plasmacytoma or metastasis. There is a significant narrowing of 
the spinal canal. Pre-operative biochemical tests showed aPTT of 
91 s for test and 30 s for control. Factor VIII assay showed level 
below 1%. Prothrombin time was within normal limits. Complete 
blood count and renal function tests were within normal limits. 
Platelet count 2.5 Lakhs/ml; Plasma fibrinogen 2.7 mg/dl. Liver 
functions showed elevated serum alkaline phosphatase of 116 
U/L (Normal 28–74 U/L). Renal function tests, serum electrolytes 
within normal limits.
ABSTRACT
Hemophilia is mostly an inherited genetic disorder, caused by mutations in the clotting factor gene. With the available 
treatment options, life expectancy of a hemophilic patient is usually of that of the general population. Hence, it is not 
uncommon that they present for surgical procedures. However, hemophilic patients for the major surgical procedure are 
always a real challenge for the perioperative physician. We have recently encountered one such patient who was hospitalized 
with acute paraplegia due to a mass lesion of spine and successfully managed with the recovery of motor power. His pre-
operative Factor VIII level was 0. Desmopressin nasal spray has a limited role in severe hemophilic. Our main concern was 
effective replacement therapy and maintenance of desired Factor VIII levels not only during surgery but also in the immediate 
post-operative period.
Key words: Acute paraplegia Acute spinal decompression, Hemophilic spine
Rajesh et al. Hemophilic patient for spine surgery
Vol 4 | Issue 2 | Mar - Apr 2018 Indian J Case Reports 116
The patient was posted for dorsal laminectomy and 
decompression of mass lesion with Moss-Miami fixation. With 
the challenge of attaining optimal Factor VIII levels perioperative 
period, replacement therapy was initiated. In the absence of 
Factor VIII inhibitors, each unit of Factor VIII infused is known 
to increase levels of Factor VIII by 2 IU/dl [5]. Consequently; 
he was administered with Factor VIII starting 1 h before the 
procedure with the target of attaining Factor VIII levels at 
100%. Calculated dose was given as a continuous infusion, 
and factor level monitored. Desmopressin nasal spray is given 
preoperatively at a dose of 300 µg 2 h before the procedure. 
Desmopressin can increase Factor VIII and von Willebrand factor 
levels and by their release from stored endothelial cells [6]. Von 
Willebrand is a glycoprotein and is necessary to carry Factor VIII 
in circulation [7].
Preoperatively under local anesthesia and ultrasound guidance, 
we have cannulated left radial for invasive hemodynamic 
monitoring and blood collections. Right internal jugular vein 
cannulated with a triple lumen 18 G jugular cannula. Routine 
five-lead electrocardiogram, pulse oximetry, neuromuscular 
monitoring, temperature probe (nasopharyngeal probe) as well 
as blood samplings for activated coagulation test, and arterial 
blood gas analysis were done during surgery. Thiopentone 
sodium was used for induction and atracurium used as a muscle 
relaxant. Fentanyl and intravenous paracetamol were used for 
perioperative analgesia. Synthetic antifibrinolytic tranexamic 
acid is given as a loading dose of 10 mg/kg and maintained at 
1 mg/kg/h [8]. Surgical colleagues reported normal hemostasis 
during the perioperative period. The patient was reversed with 
neostigmine and atropine and extubated uneventfully. Factor 
VIII levels were monitored in the post-operative period and 
maintained in arranges of 80–90% with replacement therapy. 
The patient had an uneventful post-operative course with normal 
wound drain and recovery of motor function and discharged 
uneventfully.
DISCUSSION
The main challenge in managing the hemophilic patient for 
surgery is maintaining proper hemostasis. This is achieved by 
doing specific investigations to assess coagulation status and 
meticulous replacement strategies. Care should be given for 
proper positioning of the patient throughout the intraoperative 
period and avoiding pressure points. Comprehensive pre-
operative assessment plan should also include inhibitor screening 
and assay [9]. This is all the more important when the anticipated 
Factor VIII levels are less than expected after replacements [10]. 
It is important to maintain an adequate level of Factor VIII in 
the extended post-operative period, till adequate tissue healing is 
achieved.
Re-bleeding can occur in the post-operative period after a 
period of hemostasis. This happens due to lysis of formed clot. 
Factor VIII is available in different strengths with each vial 
contains 250–3000 units each. Half-life of infused Factor VIII 
is 8–12 h. Desmopressin is useful to increase Factor VIII levels 
in mild and moderate hemophilics [6]. It is important for the 
anesthesiologist to maintain healthy communication between 
the lab personal, pharmacist, hematologist, and surgeon. Before 
committing to the perioperative care, anesthesiologist should 
make sure enough availability of adequate blood components 
and Factor VIII. For optimal support from blood banks and 
pharmacy, it is better to have the surgery scheduled at the 
beginning of the week and particularly in the morning sessions. 
Often overlooked but imperative aspect of the management 
is to monitor Factor VIII inhibitor levels, especially when the 
patient is on continuous replacement protocol. They are at high 
risk of development of antibodies [10]. There is no convincing 
literature to support the use of Tranexamic acid specifically in 
hemophilic. However, there is evidence to support its usefulness 
in spine surgery [11] and von Willebrand disease [12]. There is 
a specific recommendation of maintaining Factor VIII levels 
for 10–14 days with replacement therapy after performing 
laminectomy [13].
CONCLUSION
A hemophilic patient for spinal surgery is a real challenge; 
especially, when they present with acute paraplegia, warranting 
emergency spinal decompression. With a multidisciplinary team, 
approach and protocol based timely intervention in replacement 
therapy; these groups of patients can be safely and effectively 
managed. A major procedure like spine decompression requires 
100% replacements of Factor VIII before the procedure. It is 
important to maintain Factor VIII levels in the post-operative 
period also till satisfactory tissue healing is achieved.
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